STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 208.45

Change

+0.35 (+0.17)%

Market Cap

USD 0.66B

Volume

686.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.23 (-0.52%)

USD 56.03B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+0.50 (+0.10%)

USD 13.60B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+0.32 (+0.09%)

USD 11.29B
WRD:PA HSBC MSCI World UCITS ETF

+0.02 (+0.06%)

USD 11.04B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+0.54 (+0.21%)

USD 10.45B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+2.75 (+0.59%)

USD 7.99B
WLD:PA Lyxor UCITS MSCI World D-EUR

+0.29 (+0.08%)

USD 7.49B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

+0.11 (+1.66%)

USD 7.42B
HHH:PA HSBC S&P 500 UCITS ETF

+0.05 (+0.09%)

USD 7.22B
SPY4:PA SSgA SPDR S&P 400 US Mid Cap

-0.29 (-0.35%)

USD 5.38B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.50% 36% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.50% 34% F 38% F
Trailing 12 Months  
Capital Gain -10.17% 6% D- 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.17% 6% D- 30% F
Trailing 5 Years  
Capital Gain 28.25% 34% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.25% 33% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 8.96% 58% F 65% D
Dividend Return 8.96% 56% F 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.52% 72% C 85% B
Risk Adjusted Return 105.25% 89% A- 92% A
Market Capitalization 0.66B 70% C- 72% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike